|

TOP STORIES
Landmark Stem Cells Trial Yields Positive Results
The Phase I trial of HuCNS-SC (purified human neural stem cells) conducted at OHSU Doernbecher Children's Hospital included six children with advanced stages of infantile and late-infantile neuronal ceroid lipofuscinosis, often referred to as Batten disease.

|
|
INDUSTRY
Connexon Creative Launches Mammary Cell News
Mammary Cell News is a weekly e-newsletter that keeps members of the mammary cell community informed by providing the latest news from all areas of the field, including its science, research and business.
Subscribe Today
Viewed Archived Issues
NIH Funds Einstein Center to Target HIV-related Brain Disease
The National Institute on Drug Abuse of the National Institutes of Health has awarded a three-year, $3-million grant to Albert Einstein College of Medicine of Yeshiva University to establish a research center to study the neurological complications that afflict people infected with HIV, the virus that causes AIDS.
ReNeuron Signs Manufacturing Contract to Provide Stem Cells for Stroke Clinical Trial
ReNeuron Group plc recently announced that it has signed a contract with Angel Biotechnology Holdings plc, under which Angel will manufacture clinical-grade ReN001 stem cell lots for ReNeuron's Phase I clinical trial with its ReN001 therapy in disabled stroke patients.
ThermoGenesis Nabs NIH Grant for Stem Cell Delivery
ThermoGenesis Corp. said recently it has received a grant from the National Institute of Health to study and develop biomaterials that can be used to deploy placental stem cells in bone repair and regenerative medicine applications.
Vitro Receives Adult Stem Cell Patent from the United States Patent and Trademark Office
Vitro Diagnostics, Inc., dba Vitro Biopharma, announced that it has been awarded United States Patent number 7,527,971 entitled, "Generation and Differentiation of Adult Stem Cells."
|
|
POLICY
Despite Odds, Cities Race to Bet on Biotech
At a recent global biotech convention in Atlanta, 27 states, including Hawaii and Oklahoma, paid as much as $100,000 each to entice companies on the exhibition floor. All this for a highly risky industry that has turned a profit only one year in the past four decades.
Bob Klein to Leave CIRM Chairman Job
Bob Klein, the architect of California's $3 billion stem cell research funding program, will not seek a new term as chairman of the agency.
|
|
|
This email was sent by: Connexon Creative
400-570 W. 7th Avenue Vancouver, British Columbia V5Z 1B3 Canada |
|
|